Tempus confirmed the acquisition of the pharmacogenetics assets of OneOme, the Mayo Clinic spinoff that abruptly ceased operations in November. The deal transfers OneOme’s RightMed PGx test and partnerships with dozens of health systems to Tempus, which already offers pharmacogenomic testing as part of its oncology and precision medicine suite. Sources say the transaction is as much about OneOme’s customer contracts and clinical relationships as about technology. The move accelerates consolidation in PGx testing, raises questions about continuity of care for OneOme’s customers, and strengthens Tempus’ bid to expand into clinical pharmacogenomics across health systems. Regulators and payers will watch commercialization and integration plans closely.